All In Biotech

Drug Trial Radar · NCT06057038

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

8

Actual

Start

Nov 24, 2023

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese participants. The main purpose is to assess the safety and tolerability of GEN1042 monotherapy or GEN1042 in combination in Japanese study participants with cancer.

Conditions

  • Malignant Solid Tumor

Interventions

  • GEN1042Biological

    Intravenous

  • PembrolizumabDrug

    Intravenous

  • CisplatinDrug

    Intravenous

  • CarboplatinDrug

    Intravenous

  • 5-FluorouracilDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: During the first cycle (Cycle length = 21 days)
  2. Percentage of Participants with Adverse Events (AEs)Time frame: From first dose until the end of the treatment (approximately 3 years)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center East

    Kashiwa, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • Tokyo Medical University Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.